Cargando…

Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model

Equine influenza is a leading cause for respiratory illness in equines. Major control measures involve vaccination which requires continuous harmonization owing to antigenic drift. The present study focused on assessing the protective efficacy of an inactivated recombinant equine influenza virus (rg...

Descripción completa

Detalles Bibliográficos
Autores principales: MATHEW, Manu Kurian, VIRMANI, Nitin, BERA, Bidhan Chandra, ANAND, Taruna, KUMAR, Ramesh, BALENA, Venkataramireddy, SANSANWAL, Rekha, PAVULRAJ, Selvaraj, SUNDARAM, Karthik, VIRMANI, Meenakshi, TRIPATHI, Bhupendra Nath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Veterinary Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943333/
https://www.ncbi.nlm.nih.gov/pubmed/31656240
http://dx.doi.org/10.1292/jvms.19-0399
_version_ 1783484870147702784
author MATHEW, Manu Kurian
VIRMANI, Nitin
BERA, Bidhan Chandra
ANAND, Taruna
KUMAR, Ramesh
BALENA, Venkataramireddy
SANSANWAL, Rekha
PAVULRAJ, Selvaraj
SUNDARAM, Karthik
VIRMANI, Meenakshi
TRIPATHI, Bhupendra Nath
author_facet MATHEW, Manu Kurian
VIRMANI, Nitin
BERA, Bidhan Chandra
ANAND, Taruna
KUMAR, Ramesh
BALENA, Venkataramireddy
SANSANWAL, Rekha
PAVULRAJ, Selvaraj
SUNDARAM, Karthik
VIRMANI, Meenakshi
TRIPATHI, Bhupendra Nath
author_sort MATHEW, Manu Kurian
collection PubMed
description Equine influenza is a leading cause for respiratory illness in equines. Major control measures involve vaccination which requires continuous harmonization owing to antigenic drift. The present study focused on assessing the protective efficacy of an inactivated recombinant equine influenza virus (rgEIV) vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model. The rgEIV was generated using reverse genetics by incorporating HA and NA segments from EIV/H3N8, clade 2-Florida sublineage in an A/WSN/33 /H1N1 backbone and inactivated by formalin. The vaccine was prepared by mixing inactivated rgEIV with Montanide(TM) Pet Gel adjuvant followed by intranasal inoculation into BALB/c mice intranasally. The immune responses and protective efficacy of the vaccine was evaluated by measurement of antibody titer, immunoglobulin subtyping, cytokines, clinical signs and pathological lesions after immunization and challenge with wild EIV. Serology and cytokine expression pattern indicated that the vaccine activated mixed Th1- and Th2-like responses of vaccine. Booster immunization stimulated strong antibody responses (HAI titre: 192 ± 28.6) at 42 days post immunization and the predominant antibody subtype was IgG1. Upregulation of interferon (IFN)-gamma, interleukin (IL)-12 and IL-2 levels indicates effective induction of Th1 type response. We found that vaccination has protected mice against equine influenza virus challenge as adjudged through a lack of nonappearance of visible clinical signs of disease, no loss of body weight loss, reduced pathology in the lungs and markedly reduced virus shedding from the respiratory tract. Therefore, we conclude that recombinant EIV vaccine candidate adjuvanted with Montanide(TM) Pet Gel could aid in quick harmonization of the vaccines through replacement of HA and NA genes for control of EIV outbreaks.
format Online
Article
Text
id pubmed-6943333
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Japanese Society of Veterinary Science
record_format MEDLINE/PubMed
spelling pubmed-69433332020-01-08 Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model MATHEW, Manu Kurian VIRMANI, Nitin BERA, Bidhan Chandra ANAND, Taruna KUMAR, Ramesh BALENA, Venkataramireddy SANSANWAL, Rekha PAVULRAJ, Selvaraj SUNDARAM, Karthik VIRMANI, Meenakshi TRIPATHI, Bhupendra Nath J Vet Med Sci Virology Equine influenza is a leading cause for respiratory illness in equines. Major control measures involve vaccination which requires continuous harmonization owing to antigenic drift. The present study focused on assessing the protective efficacy of an inactivated recombinant equine influenza virus (rgEIV) vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model. The rgEIV was generated using reverse genetics by incorporating HA and NA segments from EIV/H3N8, clade 2-Florida sublineage in an A/WSN/33 /H1N1 backbone and inactivated by formalin. The vaccine was prepared by mixing inactivated rgEIV with Montanide(TM) Pet Gel adjuvant followed by intranasal inoculation into BALB/c mice intranasally. The immune responses and protective efficacy of the vaccine was evaluated by measurement of antibody titer, immunoglobulin subtyping, cytokines, clinical signs and pathological lesions after immunization and challenge with wild EIV. Serology and cytokine expression pattern indicated that the vaccine activated mixed Th1- and Th2-like responses of vaccine. Booster immunization stimulated strong antibody responses (HAI titre: 192 ± 28.6) at 42 days post immunization and the predominant antibody subtype was IgG1. Upregulation of interferon (IFN)-gamma, interleukin (IL)-12 and IL-2 levels indicates effective induction of Th1 type response. We found that vaccination has protected mice against equine influenza virus challenge as adjudged through a lack of nonappearance of visible clinical signs of disease, no loss of body weight loss, reduced pathology in the lungs and markedly reduced virus shedding from the respiratory tract. Therefore, we conclude that recombinant EIV vaccine candidate adjuvanted with Montanide(TM) Pet Gel could aid in quick harmonization of the vaccines through replacement of HA and NA genes for control of EIV outbreaks. The Japanese Society of Veterinary Science 2019-10-28 2019-12 /pmc/articles/PMC6943333/ /pubmed/31656240 http://dx.doi.org/10.1292/jvms.19-0399 Text en ©2019 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Virology
MATHEW, Manu Kurian
VIRMANI, Nitin
BERA, Bidhan Chandra
ANAND, Taruna
KUMAR, Ramesh
BALENA, Venkataramireddy
SANSANWAL, Rekha
PAVULRAJ, Selvaraj
SUNDARAM, Karthik
VIRMANI, Meenakshi
TRIPATHI, Bhupendra Nath
Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model
title Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model
title_full Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model
title_fullStr Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model
title_full_unstemmed Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model
title_short Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model
title_sort protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with montanide(tm) pet gel in murine model
topic Virology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943333/
https://www.ncbi.nlm.nih.gov/pubmed/31656240
http://dx.doi.org/10.1292/jvms.19-0399
work_keys_str_mv AT mathewmanukurian protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel
AT virmaninitin protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel
AT berabidhanchandra protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel
AT anandtaruna protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel
AT kumarramesh protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel
AT balenavenkataramireddy protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel
AT sansanwalrekha protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel
AT pavulrajselvaraj protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel
AT sundaramkarthik protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel
AT virmanimeenakshi protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel
AT tripathibhupendranath protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel